

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)	AGENT/Indication(s)	ICD-9 Code(s)
Alemtuzumab (Campath) J9010 10 mg Chronic Lymphocytic Leukemia	204.1_	Bexarotene (Targretin) Cutaneous T-Cell Lymphoma ¹	202.1_, 202.2_, 202.8_
Alitretinoin (Panretin) Kaposi's Sarcoma (topical)	176._	Bicalutamide (Casodex) Prostate ¹	185
Altretamine (Hexalen) Lung ¹ (small cell) Ovary ¹	162._ 183.0	Bleomycin (Blenoxane) J9040 15 units Cervix Esophagus ¹ Head & Neck Hodgkin's Lymphoma Kaposi's Sarcoma Malignant Peritoneal Effusion ¹ Malignant Pleural Effusion Melanoma ¹ Non-Hodgkin's Lymphomas Osteosarcoma ¹ Ovary (germ cell) Pancreas ¹ ★★★ Penis Skin Soft-Tissue Sarcomas ¹ Squamous Cell Carcinomas of Skin Testes Thyroid ¹ Vulva Trophoblastic Neoplasms	180._ 150._ 140._ to 149._, 160._, 161._, 195.0 201._ _ 176._ 197.6 197.2 172._ 200.__, 202._ _ 170._, 198.5 183.0, 183.9 157._ 187.1 to 187.4 173._ 171._ 173._ 186._ 193 184.4 236.1
Amifostine (Ethiol) J0207 500 mg Bone marrow toxicity, cisplatin-and cyclophosphamide-induced (prophylaxis), advanced solid tumors (140.0 to 203.8, 283.__ to 285.9, 995.2, V58.1, E933.1°) Bone marrow toxicity, cisplatin-induced (prophylaxis), head and neck carcinoma (140.0_ to 149.0_, 160.__ to 161._, 195.0, 995.2, V58.1, E933.1°) Bone marrow toxicity, cyclophosphamide-induced (prophylaxis), malignant lymphoma (200.__ to 202._, 283.__ to 285.9, 995.2, V58.1, E933.1°) Bone marrow toxicity, carboplatin-induced (prophylaxis), non-small cell lung cancer (162.0 to 162.9, 283.__ to 258.9, 995.2, V58.1, E933.1°) Bone marrow toxicity, carboplatin-induced (prophylaxis) plus radiation therapy, head and neck carcinoma (140.__ to 149._, 160.__ to 161._, 195.0, 995.2, V58.0, V58.1) Myelodysplastic Syndromes ¹ ★★★ 238.7 Nephrotoxicity, cisplatin-induced (prophylaxis), advanced ovarian carcinoma, melanoma, non-small cell lung carcinoma, advanced solid tumors of non-germ cell origin (162.2 to 162.9, 183._, 198.6, 172._, 583.9, 995.2, V58.1, E933.1°) Neurotoxicity, cisplatin-induced (prophylaxis), neuropathy and ototoxicity (357.6, 388.5, 389.12, 995.2, V58.1, E933.1°) Reduction in the incidence of mucositis in patients receiving radiation therapy or radiation combined with chemotherapy (101, 990, 995.2, V58.0, V58.1) ¹ Reduction in the incidence of xerostomia associated with post-operative radiation treatment of head and neck cancer, where the radiation port includes a substantial portion of the parotid glands (V58.0, 140.__ to 149._, 160.__ to 161._, 195.0, 527.7, 990) (Please consult your coding manual.)		Bortezomib (Velcade) Multiple Myeloma ³	203.0_
Aminoglutethimide (Cytadren) ACTH-Producing Tumors Adrenal Cortex ¹ Breast ¹ Prostate ¹	194.0, 194.3, 198.89, 234.8, 227.3, 237.0, 162._, 164.0, 157._, 193 194.0 174._, 175._ 185	Busulfan (Myleran) Acute Nonlymphocytic Leukemia ¹ Brain ¹ ★★★ Chronic Myelocytic Leukemia Preparative therapy in treatment of malignancies with BMT	205.0_ 191._ 205.1_
Anastrozole (Arimidex) Breast	174._, 175._	Capecitabine (Xeloda) Breast Colorectal	174._, 175._ 153._, 154._
Arsenic Trioxide (Trisenox) J9017 1 mg Acute Myelocytic Leukemia ★★★ Acute Promyelocytic Leukemia Chronic Lymphocytic Leukemia ★★★ Chronic Myeloid Leukemia ★★★ Liver ★★★ Multiple Myeloma ★★★ Myelodysplastic Syndromes ★★★	205.0_ 205.0_ 204.1_ 205.1_ 155._ 203.0_ 238.7	Carboplatin (Paraplatin Paraplatin Solution) J9045 50 mg Bladder Brain 191._ Breast ¹ Carcinoma of unknown primary ¹ Cervix ³ Endometrium ¹ Esophagus ¹ Fallopian tube ¹ Head & Neck Hodgkin's Lymphoma ¹ Lung Melanoma ¹ Neuroblastoma ³ xx Non-Hodgkin's Lymphoma ¹ Ovary Peritoneal ¹ Retinoblastoma Testes Wilms' Tumor ³ xx	188._ 174._, 175._ 199.0, 199.1 180._ 182.0 150._ 183.2 140._ to 149._, 160._, 161._, 195.0 201._ _ 162._ 172._ 160._, 194._ 200.__, 202._ _ 183.0 158.8, 158.9, 197.6 190.5 186._ 189.0
Asparaginase (Elspar, Kidrolase) J9020 10,000 units Acute Lymphocytic Leukemia Acute Nonlymphocytic Leukemia ³ (Childhood acute myeloid Leukemia) ★Non-Hodgkin's Lymphomas ^{1, 3}	204.0_ 205.0_ 200.0_, 200.1_		

PARAPLATIN® RoXLY

(carboplatin aqueous solution) INJECTION

Brief Summary of Prescribing Information, 6/03. For complete prescribing information, please consult official package circular.

WARNING
PARAPLATIN® (carboplatin aqueous solution) INJECTION should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.
Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug-related side effect.
Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of PARAPLATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.

INDICATIONS
Initial Treatment of Advanced Ovarian Carcinoma: PARAPLATIN (carboplatin aqueous solution) INJECTION is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. Two randomized controlled studies conducted by the NCI and SWOG with carboplatin and cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see **CLINICAL STUDIES** in full prescribing information). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (>3 years) because of the small number of patients with these outcomes; the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. **Secondary Treatment of Advanced Ovarian Carcinoma:** PARAPLATIN INJECTION is indicated for the secondary treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.

CONTRAINDICATIONS
PARAPLATIN INJECTION is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds. PARAPLATIN should not be employed in patients with severe bone marrow depression or significant bleeding.

WARNINGS
Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during PARAPLATIN therapy. In combination with cyclophosphamide, median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses of PARAPLATIN should not be repeated until leukocyte, neutrophil, and platelet counts have recovered. Since anemia is cumulative, transfusions may be needed during treatment with PARAPLATIN, particularly in patients receiving prolonged therapy. Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial PARAPLATIN dosages in these patients should be appropriately reduced (see **DOSE AND ADMINISTRATION**) and blood counts should be carefully monitored between courses. The use of PARAPLATIN in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects. Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or ototoxicity, and caution must be exercised when a patient receives both drugs. Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents. PARAPLATIN can induce emesis, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of emesis have been reduced by using premedication with antiemetics. Although no conclusive efficacy data exist with the following schedules of PARAPLATIN, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over five consecutive daily pulse doses has resulted in reduced emesis. Although peripheral neurotoxicity is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin. Pre-existing cisplatin-induced neurotoxicity does not worsen in about 70% of the patients receiving carboplatin as secondary treatment. Loss of vision, which can be complete for light and colors, has been reported after the use of carboplatin with doses higher than those recommended in the package insert. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses. As in the case of other platinum-coordination compounds, allergic reactions to carboplatin have been reported. These may occur within minutes of administration and should be managed with appropriate supportive therapy. There is increased risk of allergic reactions including anaphylaxis in patients previously exposed to platinum therapy. (See **CONTRAINDICATIONS** and **ADVERSE REACTIONS: Allergic Reactions**.) High dosages of carboplatin (more than four times the recommended dose) have resulted in severe abnormalities of liver function tests. PARAPLATIN (carboplatin aqueous solution) INJECTION may cause fetal harm when administered to a pregnant woman. Carboplatin has been shown to be embryonic and teratogenic in rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

PRECAUTIONS
General: Needles or intravenous administration sets containing aluminum parts that may come in contact with PARAPLATIN INJECTION should not be used for the preparation or administration of the drug. Aluminum can react with carboplatin causing precipitate formation and loss of potency. **Drug Interactions:** The renal effects of nephrotoxic compounds may be potentiated by PARAPLATIN. **Carcinogenesis, Mutagenesis, Impairment of Fertility:** The carcinogenic potential of carboplatin has not been studied, but compounds with similar mechanisms of action and mutagenicity profiles have been reported to be carcinogenic. Carboplatin has been shown to be mutagenic both *in vitro* and *in vivo*. It has also been shown to be embryonic and teratogenic in rats receiving the drug during organogenesis. Secondary malignancies have been reported in association with multi-drug therapy. **Pregnancy:** Pregnancy Category D (see **WARNINGS**). **Nursing Mothers:** It is not known whether carboplatin is excreted in human milk. Because there is a possibility of toxicity to nursing infants secondary to PARAPLATIN treatment of the mother, it is recommended that breast feeding be discontinued if the mother is treated with PARAPLATIN INJECTION. **Pediatric Use:** Safety and effectiveness in pediatric patients have not been established (see **WARNINGS**, "audiologic toxicity"). **Geriatric Use:** Of 789 patients in initial treatment combination therapy studies (NCI and SWOG), 395 patients were treated with carboplatin in combination with cyclophosphamide. Of these, 141 were over 65 years of age and 22 were 75 years of age or older. These patients had not a prognostic factor for survival. In terms of safety, elderly patients treated with carboplatin were more likely to develop severe thrombocytopenia than younger patients. In a combined database of 1942 patients (414 were >65 years of age) that received single-agent carboplatin for different tumor types, a similar incidence of adverse events was seen in patients 65 years and older and in patients less than 65. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Because renal function is often decreased in the elderly, renal function should be considered in the selection of PARAPLATIN dosage (see **DOSE AND ADMINISTRATION**).

ADVERSE REACTIONS
For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see **CLINICAL STUDIES: Comparative Toxicity** in full prescribing information.

	ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER	
	First Line Combination Therapy* Percent	Second Line Single Agent Therapy** Percent
Bone Marrow		
Thrombocytopenia	<100,000/mm ³ 66 <50,000/mm ³ 33	62 35
Neutropenia	<2,000 cells/mm ³ 86 <1,000 cells/mm ³ 67	87 61
Leukopenia	<4,000 cells/mm ³ 97 <2,000 cells/mm ³ 71	85 26
Anemia	<11 g/dL 90 <8 g/dL 14	90 21
Infections	16	5
Bleeding	8	5
Transfusions	35	44
Gastrointestinal		
Nausea and vomiting	93	92
Vomiting	83	81
Other GI side effects	46	21
Neurologic		
Peripheral neuropathies	15	6
Ototoxicity	12	1
Other sensory side effects	5	1
Central neurotoxicity	26	5
Renal		
Serum creatinine elevations	6	10
Blood urea elevations	17	22
Hepatic		
Bilirubin elevations	5	5
SGOT elevations	20	19
Alkaline phosphatase elevations	29	37
Electrolyte loss		
Sodium	10	47
Potassium	16	28
Calcium	16	31
Magnesium	61	43
Other side effects		
Fatigue	44	23
Asthenia	41	13
Cardiovascular	19	6
Respiratory	10	6
Allergic	11	2
Genitourinary	10	2
Alpecia	4	2
Mucositis	8	1

*Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCI (see **CLINICAL STUDIES** in full prescribing information). Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table.

Single Agent Use for the Secondary Treatment of Ovarian Cancer: Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single-agent carboplatin. In the narrative section that follows, the incidences of adverse events are based on data from 1893 patients with various types of tumors who received carboplatin as single-agent therapy. **Hematologic Toxicity: Bone marrow suppression is the dose-limiting toxicity of PARAPLATIN (carboplatin lyophilized powder) for INJECTION. Thrombocytopenia with platelet counts below 50,000/mm³ occurs in 25% of the patients (35% of pretreated ovarian cancer patients); neutropenia with granulocyte counts below 1000/mm³ occurs in 16% of the patients (21% of pretreated ovarian cancer patients); leukopenia with WBC counts below 2000/mm³ occurs in 15% of the patients (25% of pretreated ovarian cancer patients). The nadir usually occurs about day 21 in patients receiving single-agent therapy. By day 28, 90% of patients have platelet counts above 100,000/mm³; 74% have neutrophil counts above 2000/mm³; 67% have leukocyte counts above 4000/mm³. Marrow suppression is usually more severe in patients with impaired kidney function. Patients with poor performance status have also experienced a higher incidence of severe leukopenia and thrombocytopenia. The hematologic effects, although usually reversible, have resulted in infectious or hemorrhagic complications in 5% of the patients treated with carboplatin, with drug related death occurring in less than 1% of the patients. Fever has also been reported in patients with neutropenia. Anemia with hemoglobin less than 11 g/dL has been observed in 71% of the patients who started therapy with a baseline above that value. The incidence of anemia increases with increasing exposure to PARAPLATIN. Transfusions have been administered to 26% of the patients treated with carboplatin (44% of previously treated ovarian cancer patients). Bone marrow depression may be more severe when PARAPLATIN is combined with other bone marrow suppressing drugs or with radiotherapy. **Gastrointestinal Toxicity:** Vomiting occurs in 65% of the patients (81% of previously treated ovarian cancer patients) and in about one-third of these patients it is severe. Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously treated with emetogenic agents, especially cisplatin, appear to be more prone to vomiting. Nausea alone occurs in an additional 10% to 15% of patients. Both nausea and vomiting usually cease within 24 hours of treatment and are often responsive to antiemetic measures. Although no conclusive efficacy data exist with the following schedules, prolonged administration of carboplatin, either by continuous 24-hour infusion or by daily pulse doses given for 5 consecutive days, was associated with less severe vomiting than the single dose intermittent schedule. Emesis was increased when carboplatin was used in combination with other emetogenic compounds. Other gastrointestinal effects observed frequently were pain, in 17% of the patients; diarrhea, in 6%; and constipation, also in 6%. **Neurologic Toxicity:** Peripheral neuropathies have been observed in 4% of the patients receiving carboplatin (6% of pretreated ovarian cancer patients) with mild paresthesias occurring most frequently. Carboplatin therapy produces significantly fewer and less severe neurologic side effects than does therapy with cisplatin. However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased risk (10%) for peripheral neuropathies. In 70% of the patients with pre-existing cisplatin-induced peripheral neurotoxicity, there was no worsening of symptoms during therapy with carboplatin. Clinical ototoxicity and other sensory abnormalities such as visual disturbances and change in taste have been reported in only 1% of the patients. Central nervous system symptoms have been reported in 5% of the patients and appear to be most often related to the use of antiemetics. Although the overall incidence of peripheral neurologic side effects induced by carboplatin is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative neurotoxicity. **Nephrotoxicity:** Development of abnormal renal function test results is uncommon, despite the fact that carboplatin is significantly less nephrotoxic than cisplatin. The incidences of abnormal renal function tests reported are 6% for serum creatinine and 14% for blood urea nitrogen (10% and 22%, respectively, in pretreated ovarian cancer patients). Most of these reported abnormalities have been mild and about one-half of them were reversible. Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving carboplatin, and it appears to be the most useful test for correlating drug clearance and bone marrow suppression. Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during carboplatin therapy. **Hepatic Toxicity:** The incidences of abnormal liver function tests in patients with normal baseline values were reported as follows: total bilirubin, 5%; SGOT, 15%; and alkaline phosphatase, 24% (5%, 19%, and 37%, respectively, in pretreated ovarian cancer patients). These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of metastatic tumor in the liver may complicate the assessment in many patients. In a limited series of patients receiving very high dosages of carboplatin and autologous bone marrow transplantation, severe abnormalities of liver function tests were reported.

Electrolyte Changes: The incidences of abnormally decreased serum electrolyte values reported were as follows: sodium, 23%; potassium, 20%; calcium, 22%; and magnesium, 29% (47%, 28%, 31%, and 43%, respectively, in pretreated ovarian cancer patients). Electrolyte supplementation was not routinely

administered concomitantly with carboplatin, and these electrolyte abnormalities were rarely associated with symptoms. **Allergic Reactions:** Hypersensitivity to carboplatin has been reported in 2% of the patients. These allergic reactions have been similar in nature and severity to those reported with other platinum-containing compounds, i.e., rash, urticaria, erythema, pruritus, and rarely bronchospasm and hypotension. Anaphylactic reactions have been reported as part of postmarketing surveillance (see **WARNINGS**). These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy. **Injection Site Reactions:** Injection site reactions, including redness, swelling, and pain, have been reported during postmarketing surveillance. Necrosis associated with extravasation has also been reported. **Other Events:** Pain and asthenia were the most frequently reported miscellaneous adverse effects; their relationship to the tumor and to anemia was likely. Alopecia was reported (3%). Cardiovascular, respiratory, genitourinary, and mucosal side effects have occurred in 6% or less of the patients. Cardiovascular events (cardiac failure, embolism, cerebrovascular accidents) were fatal in less than 1% of the patients and did not appear to be related to chemotherapy. Cancer-associated hemolytic uremic syndrome has been reported rarely. Malaise, anorexia and hypertension have been reported as part of postmarketing surveillance.

OVERDOSAGE
There is no known antidote for PARAPLATIN (carboplatin aqueous solution) INJECTION overdose. The anticipated complications of overdose would be secondary to bone marrow suppression and/or hepatic toxicity.

DOSE AND ADMINISTRATION
NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of PARAPLATIN, Single-Agent Therapy: PARAPLATIN (carboplatin aqueous solution) INJECTION, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m² I.V. on day 1 every 4 weeks (alternatively see **Formula Dosing**). In general, however, single intermittent courses of PARAPLATIN should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. **Combination Therapy with Cyclophosphamide:** In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: PARAPLATIN—300 mg/m² I.V. on day 1 every four weeks for six cycles (alternatively see **Formula Dosing**). Cyclophosphamide—500 mg/m² I.V. on day 1 every four weeks for six cycles. For directions regarding the use and administration of cyclophosphamide please refer to its package insert. (See **CLINICAL STUDIES** in full prescribing information.) Intermittent courses of PARAPLATIN in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000. **Dose Adjustment Recommendations:** Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients. The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value.

Platelets	Neutrophils	Adjusted Dose* (From Prior Course)
> 100,000	> 2,000	125%
50-100,000	500-2,000	No Adjustment
< 50,000	< 500	75%

*Percentages apply to PARAPLATIN INJECTION as a single agent or to both PARAPLATIN and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended for these studies. PARAPLATIN is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced diuresis is required. **Patients with Impaired Kidney Function:** Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single-agent carboplatin therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used.

Baseline Creatinine Clearance	Recommended Dose on Day 1
41-59 mL/min	250 mg/m ²
16-40 mL/min	200 mg/m ²

The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment. These dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient's tolerance based on the degree of bone marrow suppression. **Formula Dosing:** Another approach for determining the initial dose of PARAPLATIN is the use of mathematical formulae, which are based on a patient's pre-existing renal function or renal function and desired platelet nadir. Renal excretion is the major route of elimination for carboplatin. (See **CLINICAL PHARMACOLOGY** in full prescribing information.) The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with impaired renal function). A simple formula for calculating dosage, based upon a patient's glomerular filtration rate (GFR in mL/min) and PARAPLATIN target area under the concentration versus time curve (AUC in mg•min), has been proposed by Calvert. In these studies, GFR was measured by ¹²⁵I-Cr-EDTA clearance.

CALVERT FORMULA FOR CARBOPLATIN DOSING
Total Dose (mg)=(target AUC) x (GFR + 25)
Note: With the Calvert formula, the total dose of PARAPLATIN is calculated in mg, not mg/m².

The target AUC of 4-6 mg•min using single-agent carboplatin appears to provide the most appropriate dose range in previously treated patients. This study also showed a trend between the AUC of single-agent carboplatin administered to previously treated patients and the likelihood of developing toxicity.

AUC (mg/mL•min)	% Actual Toxicity in Previously Treated Patients		
	Gr 3 or Gr 4 Thrombocytopenia	Gr 3 or Gr 4 Leukopenia	Gr 3 or Gr 4
4 to 5	16%	13%	
6 to 7	33%	34%	

Geriatric Dosing: Because renal function is often decreased in elderly patients, formula dosing of PARAPLATIN based on estimates of GFR should be used in elderly patients to provide predictable plasma PARAPLATIN AUCs and thereby minimize the risk of toxicity.

PREPARATION OF INTRAVENOUS SOLUTIONS
PARAPLATIN (carboplatin aqueous solution) INJECTION is a premixed aqueous solution of 10 mg/mL carboplatin. PARAPLATIN aqueous solution can be further diluted to concentrations as low as 0.5 mg/mL with 5% Dextrose in Water (D₅W) or 0.9% Sodium Chloride Injection, USP when prepared as directed. PARAPLATIN aqueous solutions are stable for 8 hours at room temperature (25°C). Since no antibacterial preservative is contained in the formulation, it is recommended that PARAPLATIN aqueous solutions be discarded 8 hours after dilution.



Bristol-Myers Squibb Company
Princeton, NJ 08543
U.S.A.

KB-B001A-07-03
Adapted from 3210301-1

Issued: July 2003
Based on 1165102

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)
Carmustine (BICNU) J9050 100 mg	
Brain	191._
Colorectal	153._, 154._
Cutaneous T-Cell Lymphoma ³	202.1_, 202.2_, 200.0_, 173._
Hodgkin's Lymphoma	201._ _
Melanoma	172._
Multiple Myeloma	203.0_
Non-Hodgkin's Lymphomas	200.__, 202._ _
Stomach	151._
Waldenström Macroglobulinemia ¹	273.3
Carmustine, Implantation-Local (BCNU, Gliadel)	
Brain ¹	191._
★ Cetuximab[†] (Erbix)	
Colorectal	153._, 154._
Chlorambucil (Leukeran)	
Chronic Lymphocytic Leukemia	204.1_
Cutaneous T-Cell Lymphoma ¹	201._, 202._
Hairy Cell Leukemia	202.4_
Hodgkin's Lymphoma	201._ _
Multiple Myeloma ³	203.0_
Non-Hodgkin's Lymphoma	200.__, 202._ _
Ovary (germ and nongerm cell)	183.0, 183.9
Trophoblastic Neoplasms	181, 236.1, 186.9
Waldenström Macroglobulinemia ¹	273.3
Chlorotrianisene	
Prostate	185
Chromic Phosphate P 32 (Phosphocol P32)	
Malignant Peritoneal Effusion ¹	197.6
Malignant Pleural Effusion ¹	197.2
Ovary ¹	183.0
Prostate ¹	185
Cisplatin (Platinol) J9060 10 mg, J9062 50 mg	
Adrenal Cortex	194.0
Anal	154.2, 154.3
Bladder	188._
Brain ³	191._
Breast	174._, 175._
Carcinoma of unknown primary	199.0, 199.1
Cervix	180._
Endometrium	182.0
Esophagus	150._
Fallopian tube ¹	183.2
Head & Neck	140._ to 149._, 160._, 161._, 195.0
Hodgkin's Lymphoma	201._ _
Kaposi's Sarcoma ¹	176._
Kidney ³ (Rhabdoid Tumors)	155._
Liver	155._
Lung	162._
Melanoma	172._
Mesothelioma ³	158._, 163._
Neuroblastoma	160._, 194._
Non-Hodgkin's Lymphomas	200.__, 202._ _
Osteosarcoma	170._, 198.5
Ovary (germ and nongerm cell)	183.0, 183.9
Penis ³ xx	187.1 to 187.4
Peritoneal ¹	158.8, 158.9
Prostate	185
Retinoblastoma ¹	190.5
Skin ¹	173._
Soft-Tissue Sarcomas	171._
Stomach	151._

AGENT/Indication(s)	ICD-9 Code(s)
Testes	186._
Thymoma	164.0, 164.8
Thyroid	193
Cisplatin (Platinol) (cont'd)	
Trophoblastic Neoplasms	181, 236.1, 186.9
Vulvar ¹	184.1, 184.2, 184.3, 184.4
Wilms' Tumor ¹	189.0
Cladribine, Chlorodeoxyadenosine (Leustatin) J9065 1 mg	
Chronic Lymphocytic Leukemia ¹	204.1_
Non-Hodgkin's Lymphomas (refractory, low grade) ¹	200.__, 202.0_ to 202.9_
Hairy Cell Leukemia	202.4_
Waldenström Macroglobulinemia ¹	273.3
Corticotropin	
Antiemetic (chemotherapy-induced) ¹	787.01, 787.03, 995.2
Hypercalcemia (assoc. with malignancy) ¹	275.42
Cyclophosphamide (Cytosan, Neosar) J9070-J9097	
Acute Lymphocytic Leukemia	204.0_
Acute Nonlymphocytic Leukemia	205.0_
Bladder ¹	188._
Brain ¹	191._
Breast	174._, 175._
Cervix ¹	180._
Chronic Lymphocytic Leukemia	204.1_
Chronic Myelocytic Leukemia	205.1_
Cryoglobulinemia ³	273.2
Endometrium	182.0
Ewing's Sarcoma	170._
Head & Neck ³	140._ to 149._, 160._, 161._, 195.0
Hodgkin's Lymphoma	201._ _
Kidney ¹	189.0, 189.1
Lung	162._
Macroglobulinemia ³	273.3
Multiple Myeloma	203.0_
Neuroblastoma	160._, 194._
Non-Hodgkin's Lymphomas	200.__, 202._ _
Osteosarcoma	170._, 198.5
Ovary (germ and nongerm cell)	183.0, 183.9
Preparative therapy in treatment of malignancies with BMT	
Prostate	185
Retinoblastoma	190.5
Soft-Tissue Sarcomas	171._
Thymoma ¹	164.0, 164.8
Testes	186._
Trophoblastic Neoplasms ¹	181, 236.1, 186.9
Waldenström Macroglobulinemia ¹	273.3
Wilms' Tumor	189.0
Cytarabine (Cytosar-U) J9100 100 mg, J9110 500 mg	
Acute Lymphocytic Leukemia	204.0_
Acute Nonlymphocytic Leukemia	205.0_
Chronic Myelocytic Leukemia	205.1_
Hodgkin's Lymphoma ¹	201._ _
Lymphomatous Meningitis ¹	198.4
Myelodysplastic Syndromes ¹	238.7
Non-Hodgkin's Lymphoma	200._, 202._

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)	AGENT/Indication(s)	ICD-9 Code(s)
Cytarabine Liposome Injection (DepoCyt)	J9098 10 mg	Breast	174._, 175._
Lymphomatous Meningitis†	198.4	Esophagus ¹	150._
Dacarbazine (DTIC-Dome)	J9130 100 mg, J9140 200 mg	Head & Neck ¹	140._ to 149._, 160._, 161._, 195.0
Hodgkin's Lymphoma	201._ _	Lung	162._
Melanoma	172._	Ovary ¹	183.0
Neuroblastoma ³	160._, 194._	Prostate ¹	185
Pancreas	157._	Stomach ¹	151._
Soft-Tissue Sarcomas	171._	Dolasetron Mesylate (Anzemet)	J1260 10 mg
Dactinomycin (Cosmegen)	J9120 0.5 mg	Antiemetic (Chemotherapy-induced)	787.01, 787.03, 995.2
Acute Lymphocytic Leukemia ³	204.0_	Doxorubicin (Adriamycin, RUBEX)	J9000 10 mg
Breast (Sarcoma Botryoides)	174._, 175._	Acute Lymphocytic Leukemia	204.0_
Ewing's Sarcoma	170._	Acute Nonlymphocytic Leukemia	205.0_
Kaposi's Sarcoma	176._	Adrenal Cortex ¹	194.0
Osteosarcoma	170._, 198.5	Bladder	188._
Ovary ³ xx	183._	Breast	174._, 175._
Soft-Tissue Sarcomas	171._	Carcinoid Tumors ¹	152._, 153._, 155._ to 157._, 162.2 to 162.9, 183.0, 259.2
Testes	186._	Cervix	180._
Trophoblastic Neoplasms	181, 236.1, 186.9	Chronic Lymphocytic Leukemia ¹	204.1_
Wilms' Tumor	189.0	Endometrium	182.0
Daunorubicin (Cerubidine)	J9150 10 mg	Esophagus ¹	150._
Acute Lymphocytic Leukemia	204.0_	Ewing's Sarcoma	170._
Acute Nonlymphocytic Leukemia	205.0_	Head & Neck	140._ to 149._, 160._, 161._, 195.0
Chronic Myelocytic Leukemia	205.1_	Hodgkin's Lymphoma	201._ _
Chronic Myelomonocytic Leukemia	205.10, 205.11	Kaposi's Sarcoma	176._
Ewing's Sarcoma ¹	170._	Liver ¹	155._
Kaposi's Sarcoma ³	176._	Lung	162._
Neuroblastoma ¹	160._, 194._	Multiple Myeloma	203.0_
Non-Hodgkin's Lymphomas ¹	200._ _ , 202._ _	Neuroblastoma	160._, 194._
Wilms' Tumor ¹	189.0	Non-Hodgkin's Lymphoma	200._ _ , 202._ _
Daunorubicin, Liposomal (Daunoxome)	J9151 10 mg	Osteosarcoma	170._, 198.5
Kaposi's Sarcoma	176._	Ovary (germ and nongerm cell)	183.0, 183.9
Dexamethasone	J1100 1 mg	Pancreas ¹	157._
Acute Lymphocytic Leukemia	204.0_	Prostate	185
Antiemetic (chemotherapy-induced)	787.01, 787.03, 995.2	Retinoblastoma ¹	190.5
Brain ¹	191._	Soft-Tissue Sarcomas	171._
Breast	174._, 175._	Stomach	151._
Chronic Lymphocytic Leukemia	204.1_	Testes	186._
Chronic Myelocytic Leukemia ³	205.1_	Thymoma ¹	164.0, 164.8
Hodgkin's Lymphoma	201._ _	Thyroid	193
Hypercalcemia (assoc. with malignancy)	275.42	Trophoblastic Neoplasms ¹	181, 236.1, 186.9
Multiple Myeloma ¹	203.0_	Wilms' Tumor	189.0
Non-Hodgkin's Lymphoma ³	200._ _ , 202._ _	Doxorubicin, Liposomal (Doxil)	J9001 10 mg
Prostate ¹	185	Breast ¹	174._, 175._
Dexrazoxane Hydrochloride (Zinecard)	J1190 250 mg	Kaposi's Sarcoma	176._
Breast, doxorubicin-induced cardiomyopathy prophylaxis in	174._, 175._, 995.2	Ovary	183.0
Diethylstilbestrol (DES) J9165 250mg		Epirubicin Hydrochloride (Ellence)	J9178 2mg, J9180 50 mg
Breast	174._, 175._	Breast	174._, 175._
Prostate	185	Esophagus ¹	150._
Docetaxel (Taxotere)	J9170 20 mg	Hodgkin's Lymphoma ¹	201._ _
Bladder ¹	188._	Lung ¹	162._
		Non-Hodgkin's Lymphoma ¹	200._ _ , 202._ _

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)	AGENT/Indication(s)	ICD-9 Code(s)
Ovary ¹	183.0	Etoposide Phosphate (Etopophos) J9999 100 mg	
Soft Tissue Sarcomas ¹	171._	<i>Same indications as Etoposide, previous column</i>	
Stomach ¹	151._		
Estradiol		Exemestane (Aromasin)	
Breast	174._, 175._	Breast	174._, 175._
Prostate	185		
Estradiol Valerate		Floxuridine (FUDR) J9200 500 mg	
Breast	174._, 175._	Colorectal	153._, 154._
Prostate	185	Kidney ¹	189.0, 189.1
		Liver	155._
		Ovary ¹	183.0
Estramustine (Emcyt)		Fludarabine Phosphate (Fludara) J9185 50 mg	
Prostate	185	Acute Nonlymphocytic Leukemia ³ ^{XX}	205.0_
		Chronic Lymphocytic Leukemia	204.1_
Estrogens (Conjugated & Esterified)		Cutaneous T-Cell Lymphoma ³	202.1_, 202.2_
Breast	174._, 175._	Hairy Cell Leukemia ³	202.4_
Prostate	185	Non-Hodgkin's Lymphoma	200.__, 202.__
		Polymorphocytic Leukemia	204.9_
		Waldenström Macroglobulinemia ³	273.3
Estrone		Fluorouracil (Adrucil, Efudex, Fluoroplex) J9190 500 mg	
Prostate	185	Adrenal Cortex ¹	194.0
Ethinyl Estradiol (Estinyl)		Anal ¹	154.2, 154.3
Breast	174._, 175._	Bladder	188._
Prostate	185	Breast	174._, 175._
		Carcinoid Tumors ¹	152._, 153._, 155._ to 157._, 162.2 to 162.9, 183.0, 259.2
Etidronate (Didronel) J1436 300 mg		Cervix	180._
Hypercalcemia (assoc. with malignancy)	275.42	Colorectal	153._, 154._
Paget's Disease of Bone	731.0	Endometrium ¹	182.0
		Esophagus	150._
Etoposide (Toposar, VePesid) J9181 10 mg, J9182 100 mg		Head & Neck	140._ to 149._, 160._, 161._, 195.0
Acute Lymphocytic Leukemia ¹	204.0_	Kidney ³ ^{XX}	189.0, 189.1
Acute Nonlymphocytic Leukemia	205.0_	Liver	155._
Adrenal Cortex ¹	194.0	Lung	162._
Bladder	188._	Ovary	183.0
Brain	191._	Pancreas	157._
Carcinoma of unknown primary ¹	199._	Penis ¹	187.1 to 187.4, 187.8
Cutaneous T-cell Lymphoma ¹	201._, 202._	Prostate ¹	185
Endometrium ¹	182.0	Skin (topical 5-FU)	173._
Ewing's Sarcoma	170._	Stomach	151._
Hodgkin's Lymphoma	201._ _	Vulvar ¹	184.1, 184.2, 184.3, 184.4
Kaposi's Sarcoma	176._		
Liver	155.0, 155.2	Fluoxymesterone (Halotestin)	
Lung	162._	Breast	174._, 175._
Multiple Myeloma ¹	203.0_		
Neuroblastoma	160._, 194._	Flutamide (Eulexin)	
Non-Hodgkin's Lymphoma	200.__, 202.__	Prostate	185
Osteosarcoma	170._, 198.5		
Ovary (germ and nongerm cell)	183.0, 183.9	Fulvestrant (Faslodex) J9395 25 mg	
Retinoblastoma ¹	190.5	Breast [†]	174._, 175._ ^{XX}
Soft Tissue Sarcomas	171._		
Stomach ¹	151._	★Gefitinib (Iressa)	
Testes	186._	Lung ¹	162._
Thymoma ¹	164.0, 164.8		
Trophoblastic Neoplasms	181, 236.1, 186.9		
Wilms' Tumor	189.0		

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)	AGENT/Indication(s)	ICD-9 Code(s)
Gemcitabine Hydrochloride (Gemzar)	J9201 200 mg	Osteosarcoma	170., 198.5
Bladder	188._	Ovary (germ and nongerm cells)	183., 183.9
Breast ¹	174., 175._	Pancreas ¹	157._
Gallbladder (and biliary tract) ¹	156._	Soft Tissue Sarcomas	171._
Germ Cell Tumor ¹	183.0, 186., 164.2, 164.3, 164.8, 164.9, 158., 181, 194.4	Testes (germ cell)	186._
Hodgkin's Lymphoma ¹	201._ _	Thymoma ¹	164.0, 164.8
Lung (non-small cell)	162._	Uterus ³ xx	182._
Non-Hodgkin's Lymphoma ¹	200., 202._	Wilms' Tumor	189.0
Ovary	183.0		
Pancreas	157._	Irinotecan Hydrochloride (Camptosar)	J9206 20 mg
		Cervix ³ xx	180._
Gemtuzumab Ozogamicin (Mylotarg)		Colorectal	153., 154._
Acute Myeloid Leukemia	205._ _	Lung (small-cell) ³	162._
		Lung (non small-cell) ¹	162._
Goserelin (Zoladex)	J9202 3.6mg		
Breast ¹	174., 175._	Ketoconazole (Nizoral)	
Endometrium ¹	182.0	Adrenal Cortex ³	194.0
Prostate ¹	185	Prostate	185
Granisetron Hydrochloride (Kytril)	J1626 100 mcgm		
Antiemetic (Chemotherapy-induced)	787.01, 787.03, 995.2	Letrozole (Femara)	
(Associated with radiation ¹)		Breast	174._
Hydrocortisone			
Antiemetic (chemotherapy-induced)	787.01, 787.03, 995.2	Leucovorin (Leucovorin Calcium, Wellcovorin)	J0640 50 mg
Hypercalcemia (assoc. with malignancy)	275.42	Colorectal	153., 154._
		Ewing's Sarcoma ¹	170._
Hydroxyprogesterone (Prodox)		Head & Neck ¹	140._ to 149.0, 160., 161., 195.0
Endometrium ³	182.0	Non-Hodgkin's Lymphoma ¹	200., 202._
Uterus	182._	Osteosarcoma	170., 198.5
		Trophoblastic Neoplasmas ¹	181, 236.1, 186.9
Hydroxyurea (Hydrea)			
Cervix	180._	Leuprolide (Lupron, Lupron Depot)	
Chronic Myelocytic Leukemia	205.1_	Breast	174._
Head & Neck	140._ to 149., 160., 161., 195.0	Endometrium ¹	182.0
Melanoma	172._	Prostate	185
Ovary	183.0		
Polycythemia Vera	238.4	Levodopa	
Thrombocytosis	289.9	Bone Lesions ³	170., 198.5
Idarubicin (Idamycin)	J9211 5 mg	Levothyroxine	
Acute Lymphocytic Leukemia ¹	204.0_	Thyroid	193
Acute Nonlymphocytic Leukemia	205.0_		
Chronic Myelogenous Leukemia ¹ ★★★	205.1_	Liothyronine	
		Thyroid	193
Ifosfamide (Ifex)	J9208 1 gm	Liotrix	
Acute Lymphocytic Leukemia	204.0_	Thyroid	193
Bladder	188._		
Breast ¹	174., 175._	Lomustine (CeeNU)	
Cervix	180._	Brain	191._
Endometrium ¹	182.0	Breast	174., 175._
Ewing's Sarcoma	170._	Colorectal	153., 154._
Head & Neck ¹	140._ to 149., 160., 161., 195.0	Hodgkin's Lymphoma	201._ _
Hodgkin's Lymphomas ¹	201._ _	Lung	162._
Lung	162._	Melanoma ¹	172._
Neuroblastoma ¹	160., 194._	Multiple Myeloma ¹	203.00 to 203.01
Non-Hodgkin's Lymphoma	200., 202._	Masoprocol (Actinex)	
		Skin (topical) ¹	173._

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)	AGENT/Indication(s)	ICD-9 Code(s)
Mechlorethamine (Mustargen) 9230 10 mg		Non-Hodgkin's Lymphomas	200._., 202._.
Chronic Myelocytic Leukemia	205.1_	Osteosarcoma	170._, 198.5
Cutaneous T-cell Lymphoma ¹	202.1_, 202.2_	Ovary ¹	183.0
Hodgkin's Lymphoma	201._	Pancreas ¹	157._
Lung	162._	Penis ¹	187.1 to 187.4, 187.8
Malignant Pericardial Effusion	164.1	Soft Tissue Sarcoma ¹	171._
Malignant Peritoneal Effusion	197.6	Stomach ¹	151._
Malignant Pleural Effusion	197.2	Trophoblastic Neoplasms	181, 236.1, 186.9
Non-Hodgkin's Lymphoma	200._., 202._.		
Medroxyprogesterone (Provera, Depo-Provera)		Methoxsalen (8-MOP)	
Breast	174._	Cutaneous T-Cell Lymphoma	202.1_, 202.2_
Endometrial	182.0		
Kidney	189.0, 189.1	Methyltestosterone	
		Breast	174._
Megestrol (Megace)		Mitomycin (Mutamycin) J9280 5 mg, J9290 20 mg, J9291 40 mg	
Breast	174._, 175._	Anal	154.2, 154.3
Cachexia	199.1, 799.4	Bladder	188._
Endometrial	182.0	Breast	174._, 175._
		Cervix	180._
Melphalan (Alkeran) J9245 50 mg		Chronic Myelocytic Leukemia ¹	205.1_
Breast	174._	Colorectal	153._, 154._
Chronic Myelocytic Leukemia	205.1_	Esophagus ¹	150._
Endometrial ¹	182.0	Gallbladder ¹	156.0
Hodgkin's Lymphoma ¹	201._	Head & Neck	140._ to 149._, 160._, 161._, 195.0
Melanoma	172._	Lung	162._
Multiple Myeloma	203.0_	Pancreas	157._
Osteosarcoma ³	170._, 198.5	Stomach	151._
Ovary	183.0		
Prostate ³	185	Mitotane (Lysodren)	
Soft Tissue Sarcomas ³	171._	Adrenal Cortex	194.0
Testes ³	186._		
Waldenström Macroglobulinemia ¹	273.3	Mitoxantrone (Novantrone) J9293 5 mg	
		Acute Lymphocytic Leukemia ¹	204.0_
Mercaptopurine (Purinethol, 6-MP)		Acute Nonlymphocytic Leukemia	205.0_
Acute Lymphocytic Leukemia	204.0_	Breast ¹	174._, 175._
Acute Nonlymphocytic Leukemia	205.0_	Liver ¹	155._
Chronic Myelocytic Leukemia	205.1_	Non-Hodgkin's Lymphomas	200._., 202._.
Hodgkin's Lymphoma ³	201._	Prostate	185
Non-Hodgkin's Lymphoma	200._. to 202._.		
		Nandrolone J2320 up to 50 mg, J2321 up to 100 mg, J2322 up to 200 mg	
Mesna (Mesnex) J9209 200 mg		Breast ¹	174._, 175._
Hemorrhagic Cystitis	595.82, 995.2		
(Cyclophosphamide-/Ifosfamide-induced)		Nilutamide	
		Prostate	185._
Methotrexate (Folex, Mexate) J9250 5 mg, J9260 50 mg		Ondansetron Hydrochloride (Zofran) J2405 1 mg	
Acute Lymphocytic Leukemia	204.0_	Antiemetic (chemotherapy-induced, radiotherapy-induced)	787.01, 787.03, 995.2
Acute Nonlymphocytic Leukemia	205.0_		
Bladder	188._	Oxaliplatin (Eloxatin) J9263 0.5 mg	
Brain ¹	191._	Colorectal	153._, 154._
Breast	174._, 175._		
Carcinomatous Meningitis	198.4		
Cervix ¹	180._		
Colorectal ¹	153._, 154._		
Esophagus ¹	150._		
Head & Neck	140._ to 149._, 160._, 161._, 195.0		
Hodgkin's Lymphoma ¹	201._		
Lung	162._		

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)	AGENT/Indication(s)	ICD-9 Code(s)
Paclitaxel (Taxol, Onxol) J9265 30 mg		Non-Hodgkin's Lymphomas	200._., 202._._
Bladder	188._	Prostate ¹	185
Breast	174._, 175._	Waldenström Macroglobulinemia ¹	273.3
Carcinoma of unknown primary ¹	199.0, 199.1	Procarbazine (Matulane, Natulan)	
Cervix	180._	Brain	191._
Endometrial ¹	182.0	Hodgkin's Lymphoma	201._._
Esophagus	150._	Lung	162._
Fallopian tube ¹	183.2	Multiple Myeloma ¹	203.00 to 203.01
Head & Neck	140._ to 149._, 160._, 161._, 195.0	Non-Hodgkin's Lymphomas	200._., 202._._
Lung (Non-small cell and small cell)	162._	Raltitrexed (Tomudex)	
Kaposi's Sarcoma	176._	Colorectal ¹ (Available in Canada)	153._, 154._
Ovary	183.0	Rituximab (Rituxan) J9310 100 mg	
Peritoneal ¹	158.8, 158.9	Chronic Lymphocytic Leukemia ¹	204.1_
Prostate ¹	185	Immune or Idiopathic	
Stomach ¹	151._	Thrombocytopenic Purpura ¹	287.3
Testes ¹	186._	Non-Hodgkin's Lymphomas	200._., 202._._
Palonosetron Hydrochloride (Aloxi) [†]		Waldenström Macroglobulinemia ¹	273.3
Antiemetic (Chemotherapy-induced)	787.01, 787.03, 995.2	Sodium Iodide I 131 (Idotope)	
Pamidronate Disodium (Aredia) J2430 30 mg		Thyroid ¹	193
Hypercalcemia (assoc. with malignancy)	275.42	Sodium Phosphate P 32	
Multiple Myeloma with bone metastases	203.0_ and 198.5	Bone Lesions ¹	170._, 198.5
Osteolytic Bone Metastases	174._, 175._, 198.5	Chronic Lymphocytic Leukemia ¹	204.1_
(with breast cancer/myeloma)		Chronic Myelocytic Leukemia ¹	205.1_
Paget's Disease of Bone	731.0	Streptozocin (Zanosar) J9320 1 gm	
Pegaspargase (Oncaspar) J9266 per vial		Carcinoid Tumors	152._, 153._, 154.0, 154.1, 162.2 to 162.9, 183.0, 259.2
Acute Lymphocytic Leukemia	204.0_	Colorectal ¹	153._, 154._
★Pemetrexed (Alimta)		Hodgkin's Lymphomas ³	201._._
Mesothelioma [†]	163._	Liver ³	155._
Pentostatin (Nipent) J9268 10 mg		Pancreas	157._
Acute Lymphocytic Leukemia ³	204.0_	Tamoxifen (Nolvadex)	
Chronic Lymphocytic Leukemia ^{★★★}	204.1_	Breast	174._
Cutaneous T-Cell Lymphoma ^{1★★★}	202.1_, 202.2_	Carcinoid Tumors ^{3 xx}	152._, 153._, 154.0, 154.1, 162.2 to 162.9, 183.0, 259.2
Hairy Cell Leukemia	202.4_	Endometrium ¹	182.0
Prolymphocytic Leukemia	204.9_	Melanoma ¹	172._
Plicamycin (Mithracin) J9270 2.5 mg		Temozolomide (Temodar)	
Hypercalcemia (assoc. with malignancy)	275.42	Brain ¹ (refractory anaplastic astrocytoma)	191._
Hypercalciuria (assoc. with malignancy)	275.40	Melanoma ¹	172._
Paget's Disease of Bone ¹	731.0	Teniposide (Vumon)	
Testes	186._	Acute Lymphocytic Leukemia	204.0_
Porfimer Sodium (Photofrin)		Neuroblastoma ¹	160._, 194._
Esophagus ¹	150._	Non-Hodgkin's Lymphomas ¹	200._., 202._._
Lung ¹	162._	Testolactone (Teslac)	
Prednisone (Deltasone)		Breast	174._, 175._
Acute Lymphocytic Leukemia	204.0_	Testosterone	
Antiemetic (chemotherapy-induced)	787.01, 787.03, 995.2	Breast	174., 175._
Breast	174._, 175._		
Chronic Lymphocytic Leukemia	204.1_		
Chronic Myelocytic Leukemia ³	205.1_		
Hodgkin's Lymphoma	201._._		
Hypercalcemia (assoc. with malignancy)	275.42		
Multiple Myeloma ¹	203.0_		

Generic Drug Index ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)	AGENT/Indication(s)	ICD-9 Code(s)
Thalidomide (Thalomid)		Trimetrexate J3305 25 mg	
Brain ³ xx	191._	Colorectal ¹	153._, 154._
Breast ³ xx	174._, 175._	Head & Neck ★★★	140._ to 149._, 160._, 161._, 195.0
Cachexia ³ xx	199.1, 799.4	Lung ★★★	162._
Kaposi's Sarcoma ³ xx	176._	Pancreas ★★★	157._
Kidney ³ xx	189.0, 189.1	Uracil Mustard	
Melanoma ³ xx	172._	Cervix ³	180.0
Multiple Myeloma	203.0_	Chronic Lymphocytic Leukemia	204.1_
★Myelodysplastic Syndromes ¹	238.7	Chronic Myelocytic Leukemia	205.1_
Ovary ³ xx	183.0	Hodgkin's Lymphoma ³	201._ _
Prostate ³ xx	185	Lung ³	162._
Thioguanine		Non-Hodgkin's Lymphoma	200.__, 202._ _
Acute Lymphocytic Leukemia	204.00, 204.01	Ovary ³	183.0
Acute Nonlymphocytic Leukemia	205.00 to 205.01	Valrubicin (Valstar) J9357 200 mg	
Chronic Myelocytic Leukemia	205.10, 205.11	Bladder	188._, 233.7
Thiotepa J9340 15 mg		Vinblastine (Velban) J9360 1 mg	
Bladder	188._	Bladder	188._
Breast	174._, 175._	Breast	174._, 175._
Carcinomatous Meningitis ¹	198.4	Cutaneous T-Cell Lymphoma	202.1_, 202.2_
Hodgkin's Lymphoma ¹	201._ _	Head & Neck	140._ to 149._, 161._, 195.0
Malignant Pericardial Effusion	164.1	Hodgkin's Lymphoma	201._ _
Malignant Peritoneal Effusion	197.6	Kaposi's Sarcoma	176._
Malignant Pleural Effusion	197.2	Kidney	189.0, 189.1
Ovary	183.0	Lung	162._
Thyroglobulin		Melanoma	172._
Thyroid	193	Neuroblastoma ¹	160._, 194._
Thyroid		Non-Hodgkin's Lymphomas	200.__, 202._ _
Thyroid	193	Ovary ¹ (germ cell)	183.0
Thyrotropin		Prostate ¹	185._
Thyroid	193	Testes	186._
Topotecan Hydrochloride (Hycamtin) J9350 4 mg		Trophoblastic Neoplasms	181, 236.1, 186.9
Chronic Myelomonocytic Leukemia ¹	205.1_	Vincristine (Oncovin, Vincasar) J9370 1 mg, J9375 2 mg, J9380 5 g	
Lung (small and non-small cell)	162._	Acute Lymphocytic Leukemia	204.0_
Myelodysplastic Syndromes ¹	238.7	Acute Nonlymphocytic Leukemia ³ xx	205.0_
Ovary	183.0	Brain	191._
Toremifene Citrate (Fareston)		Breast	174._, 175._
Breast	174._	Cervix ¹	180._
Trastuzumab (Herceptin) J9355 10 mg		Chronic Lymphocytic Leukemia ¹	204.1_
Breast	174._, 175._	Chronic Myelocytic Leukemia ¹	205.1_
Treosulfan (Ovastat)		Colorectal ¹	153._, 154._
Ovary ¹	183.0	Cutaneous T-Cell Lymphoma ¹	202.1_, 202.2_
Tretinoin (Vesanoid)		Ewing's Sarcoma	170._
Acute Promyelocytic Leukemia ¹	205.0_	Hodgkin's Lymphoma	201._ _
Trilostane		Kaposi's Sarcoma	176._
ACTH-Producing Tumors	194.3, 198.89, 234.8, 227.3, 237.0, 162._, 164.0, 157._, 193	Kidney	189.0, 189.1
Adrenal Cortex ¹	194.0	Liver ¹	155.0, 155.2
		Lung	162._
		Melanoma ¹	172._
		Multiple Myeloma	203.0_
		Neuroblastoma	160._, 194._
		Non-Hodgkin's Lymphoma	200.__, 202._ _
		Osteosarcoma	170._, 198.5
		Ovary ¹ (germ cell)	183.0
		Retinoblastoma ¹	190.5

Generic Drug Index

■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT/Indication(s)	ICD-9 Code(s)
Vincristine (Oncovin, Vincasar) J9370 1 mg, J9375 2 mg, J9380 5g (cont'd)	
Rhabdomyosarcoma	171._, 143.9, 158.0, 190.1, 173.9, 174.9, 175.9
Soft Tissue Sarcomas	171._
Trophoblastic Neoplasms ¹	181, 236.1, 186.9
Waldenström Macroglobulinemia ¹	273.3
Wilms' Tumor	189.0
Vinorelbine Tartrate (Navelbine) J9390 10 mg	
Breast	174._, 175._
Cervix	180._
Lung (non-small cell)	162._
Ovary ¹	183.0
Zoledronic Acid (Zometa) J3487 1 mg	
Hypercalcemia (assoc. with malignancy)	275.42
Multiple Myeloma	203.0_
Bone Metastases from solid tumors, sometimes found with breast carcinoma, multiple myeloma, non-small cell lung carcinoma, renal cell carcinoma, head and neck carcinoma, and prostate carcinoma. ¹	198.5

PUBLICATION KEY

Unless otherwise noted, drugs/indications are recognized in both compendia. Drugs marked as ★★★ have orphan drug status, and may not be reimbursed by your local carrier.

1 = USP DI

The United States Pharmacopeial Convention, Inc.
12601 Twinbrook Parkway
Rockville, MD 20852
301/881-0666

3 = AHFS Drug Information

American Society of Health System Pharmacists, Inc.
7272 Wisconsin Ave.
Bethesda, MD 20814
301/657-3000

† = FDA approved indication, not yet in compendia.

° = Local Medicare may reimburse under this code.

★ = Item has been added or changed since last issue.

xx = Check with your local Medicare carrier before submitting a claim for this indication.

■ BIOLOGICAL RESPONSE MODIFIERS AND OTHERS

AGENT/Indication(s)	ICD-9 Code(s)
Aldesleukin (Proleukin) J9015 per single dose vial	
Acute Myelogenous Leukemia ^{1,3} ★★★	205.0_
Kidney	189.0, 189.1
Melanoma	172._
Non-Hodgkin's Lymphoma ¹ ★★★	200.__, 202.__
Bacillus Calmette-Guerin (TheraCys, Tice)	
Bladder	188._
★Bevacizumab[†] (Avastin)	
Colorectal [†]	153._, 154._
Darbepoetin Alfa (Aranesp) J0880* 5 mcgm, Q0137 per 1 mcgm	
Anemia of Malignancy ¹	
Chronic Anemia (Chemotherapy-induced associated with malignancy) ¹	285.21, 285.22, 285.9, V58.1°, V66.2°
Chronic Illness (renal failure)	*for use in physician office setting only
Denileukin Diftitox (ONTAK)	
Cutaneous T-Cell Lymphoma ★★★	202.1_, 202.2_
Epoetin Alfa (Procrit, Epogen) Q0136 per 1,000 units	
Anemia of Malignancy ¹	
Chemotherapy	V58.1°
Chronic anemia (Chemotherapy-induced associated with malignancy)	285.9
Anemia associated with chronic illness (HIV, renal failure)	285.2_
Multiple Myeloma ³	203.0_
Myelodysplastic Syndromes	238.7
Reduction of allogeneic blood transfusion in anemic surgery	
Filgrastim (Neupogen) J1440 300 mcgm, J1441 480 mcgm	
Acute Myeloid Leukemia	205._ to 208.01
Chemotherapy	V66.2° or V58.1°
PBPC Mobilization	
Myelodysplastic Syndromes	238.7
Neutropenia (Chemotherapy-induced, assoc. with bone marrow transplant)	288.0
Gallium Nitrate (Ganite)	
Hypercalcemia	275.42
Gemtuzumab Ozogamacin (Mylotarg)	
Acute Myeloid Leukemia	205._ to 208.01
Imatinib Mesylate (Gleevec)	
Chronic Myelogenous Leukemia	205.1_
Gastrointestinal Stromal Tumors ¹	171.8
Immune Globulin IGIV J1561 500 mg, J1562 5 gm	
Bacterial infections (associated with B-Cell chronic lymphocytic leukemia)	790.7
Interferon Alpha-2a (Roferon A) J9213 3 million units	
Bladder	188._
Brain	191._
Carcinoid Syndrome	259.2
Chronic Lymphocytic Leukemia ³	204.1_
Chronic Myelocytic Leukemia	205.1_
Colorectal ³	153._, 154._
Cutaneous T-Cell Lymphoma	202.1_, 202.2_
Esophagus ¹	150._
Hairy Cell Leukemia	202.4
Head and Neck ³	140._ to 149._, 160._, 161._, 195.0
Kaposi's Sarcoma	176._

Generic Drug Index

■ BIOLOGICAL RESPONSE MODIFIERS AND OTHERS

INDICATION/Agent(s)	ICD-9 Code(s)
Kidney	189.0, 189.1
Melanoma	172._
Multiple Myeloma	203.0_
Non-Hodgkin's Lymphomas	200.__, 202.__
Osteosarcoma ³	170._, 198.5
Ovary	183.0
Pancreas ³	157._
Polycythemia Vera ¹	238.4
Skin	173._
Interferon Alpha-2b (Intron A, Rebetrone)	
Bladder	188._
Brain	191._
Carcinoid Syndrome	259.2
Chronic Lymphocytic Leukemia ³	204.1_
Chronic Myelocytic Leukemia	205.1_
Colorectal ³	153._, 154._
Condyloma Acuminatum	078.11
Cutaneous T-Cell Lymphoma	202.1_, 202.2_
Hairy Cell Leukemia	202.4
Head and Neck ³	140._ to 149._, 160._, 161._, 195.0
Kaposi's Sarcoma	176._
Kidney	189.0, 189.1
Melanoma	172._
Multiple Myeloma	203.0_
Non-Hodgkin's Lymphomas	200.__, 202.__
Osteosarcoma ³	170._, 198.5
Ovary	183._
Pancreas ³	157._
Polycythemia Vera ¹	238.4
Skin	173._
Levamisole (Ergamisol)	
Colorectal	153._, 154._
Octreotide (Sandostatin, Sandostatin LAR Depot)	
Carcinoid Syndrome	259.2
Chemotherapy-induced diarrhea ¹	787.91
Pancreas	157._
Oprelvekin (Neumega) J2355 5 mg	
Non-myeloid Malignancy ¹	140._ to 202._
Secondary Thrombocytopenia, due to drug therapy ¹	287.4
Pegfilgrastim (Neulasta)	
Infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs.	
Sargramostim (Leukine) J2820 50 mcgm	
Chemotherapy	V58.1°, V66.2°
Neutropenia (assoc. with bone marrow transplant, chemotherapy-induced, including chemotherapy assoc. with acute myelogenous leukemia)	288.0
Myelodysplastic Syndromes	238.7
SGN-30	
Hodgkin's Lymphoma★★★	201.__
Triptorelin Pamoate (Trelstar Depot)	
Prostate ³	185

Indication Index

INDICATION/Agent(s)	ICD-9 Code(s)
ACTH-Producing Tumors	194.3, 198.89, 234.8, 227.3,
Aminoglutethimide, Trilostane ¹	237.0, 162._, 164.0, 157._, 193
Acute Lymphocytic Leukemia	204.0_
Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Etoposide, Idarubicin, ¹ Ifosfamide, Mercaptopurine, Methotrexate, Mitoxantrone, ¹ Pegaspargase, Pentostatin ³ , Prednisone, Teniposide, Thioguanine, Vincristine	
Acute Nonlymphocytic Leukemia	205.0_
(Erythroleukemia, Meningeal, Monocytic, Myelocytic, Myelomonocytic, Promyelocytic)	
Aldesleukin ^{1,3} ★★★, Arsenic Trioxide ★★★, Asparaginase, ³ Busulfan, ¹ Cyclophosphamide, Cytarabine, Daunorubicin, Doxorubicin, Etoposide, Fludarabine Phosphate ³ XX, Gemtuzumab, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone, Thioguanine, Tretinoin, ¹ Vincristine ³ XX	
Adrenal Cortex	194.0
Aminoglutethimide, ¹ Cisplatin, Doxorubicin, ¹ Etoposide, ¹ Fluorouracil ¹ , Ketoconazole, ³ Mitotane, Trilostane ¹	
Antiemetic	787.01, 787.03, 995.2, V58.1°
Corticotropin, ¹ Dexamethasone, ¹ Dolasetron Mesylate, Granisetron Hydrochloride, Hydrocortisone, ¹ Ondansetron Hydrochloride, Palonosetron Hydrochloride [†] , Prednisone	
Bacterial Infections	790.7
(assoc. with B-cell chronic lymphocytic leukemia)	
Immune Globulin IGIV	
Bladder	188._
Bleomycin, Carboplatin, Cisplatin Cyclophosphamide, ¹ Docetaxel, ¹ Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Ifosfamide, Interferon Alpha 2a & 2b, Methotrexate, Mitomycin, Paclitaxel, Thiotepa, Valrubicin (233.7), Vinblastine	
Bone Lesions	170._, 198.5
Levodopa, ³ Sodium Phosphate P 32 ¹ , Zoledronic Acid ¹	
Brain	191._
Carboplatin, Carmustine, Cisplatin, ³ Cyclophosphamide, ¹ Dexamethasone, ¹ Etoposide, Interferon Alpha 2a, Interferon Alpha-2b, Lomustine, Methotrexate, ¹ Procarbazine, Temozolomide, ¹ Thalidomide, ³ XX Vincristine	
Breast	174._, 175._
Aminoglutethimide, ¹ Anastrozole, Capecitabine, Carboplatin, ¹ Cisplatin, Cyclophosphamide, Dactinomycin (sarcoma botryoides), Dexamethasone, Dexrazoxane, Docetaxel, Doxorubicin, Doxorubicin Liposomal, ¹ Epirubicin Hydrochloride [†] , Estradiol, Estradiol Valerate, Estrogens (Conjugated & Esterified), Ethinyl, Exemestane, Fluorouracil, Flouxymesterone, Fulvestrant [†] , Gemcitabine, ¹ Goserelin, ¹ Ifosfamide, ¹ Letrozole, Leuprolide, Lomustine, Medroxyprogesterone, Megestrol, Melphalan, Methotrexate, Methyltestosterone, Mitomycin, Mitoxantrone, ¹ Nandrolone, ¹ Pamidronate Disodium, ¹ Paclitaxel, Prednisone, Tamoxifen, Testolactone, Testosterone, Thalidomide ³ XX, Thiotepa, Toremifene, Trastuzumab, Vinblastine, Vincristine, Vinorelbine Tartrate	

Indication Index

INDICATION/Agent(s)	ICD-9 Code(s)	INDICATION/Agent(s)	ICD-9 Code(s)
Cachexia Megace, Thalidomide ³ ^{XX}	199.1, 799.4	Esophagus Bleomycin, ¹ Carboplatin, ¹ Cisplatin, Docetaxel, ¹ Doxorubicin, ¹ Epirubicin Hydrochloride, ¹ Fluorouracil, Interferon 2a, ¹ Methotrexate, ¹ Mitomycin, ¹ Paclitaxel, Porfimer Sodium ¹	150._
Carcinoid Syndrome Interferon Alpha 2a, 2b	259.2, 152._, 153._, and other malignant neoplasm codes	Ewing's Sarcoma Cyclophosphamide, Dactinomycin, Daunorubicin, ¹ Doxorubicin, Etoposide, Ifosfamide, Leucovorin, ¹ Vincristine	170._
Carcinoid Tumors Doxorubicin, ¹ Fluorouracil, ¹ Interferon Alpha 2a, 2b, Octreotide, Streptozocin, Tamoxifen ³ ^{XX}	152._, 153._, 154.0, 154.1, 162.2 to 162.9, 259.2	Fallopian Tube Carboplatin, ¹ Cisplatin, ¹ Paclitaxel ¹	183.2
Carcinoma of Unknown Primary Site Carboplatin, ¹ Cisplatin, ¹ Etoposide, ¹ Paclitaxel, ¹	190._ to 199.1	Gallbladder Gemcitabine ¹ , Mitomycin ¹	156._
Cervix Bleomycin, Carboplatin, ³ Cisplatin, Cyclophosphamide, ¹ Doxorubicin, Fluorouracil, Hydroxyurea, Ifosfamide, Irinotecan Hydrochloride ³ ^{XX} , Methotrexate, ¹ Mitomycin, Paclitaxel, Uracil Mustard, ³ Vincristine, ¹ Vinorelbine Tartrate	180._	Hairy Cell Leukemia Chlorambucil, Cladribine, Fludarabine Phosphate, ³ Interferon Alpha 2a, 2b, Pentostatin	202.4_
Chronic Anemia (associated with malignancy) Darbepoetin Alfa, ¹ Epoetin Alfa	285.9	Head & Neck Amifostine, Bleomycin, Carboplatin, Cisplatin, Cyclophosphamide, ³ Docetaxel, ¹ Doxorubicin, Fluorouracil, ¹ Hydroxyurea, ³ Ifosfamide, ¹ Interferon 2a, 2b, ³ Leucovorin, ¹ Methotrexate, Mitomycin, Paclitaxel, Trimetrexate ★★★ , Vinblastine,	140._ to 149._, 160._, 161._, 195.0
Chronic Lymphocytic Leukemia Alemtuzumab, Arsenic Trioxide ★★★ , Chlorambucil, Cladribine, ¹ Cyclophosphamide, Dexamethasone, Doxorubicin, ¹ Fludarabine Phosphate, Interferon Alpha 2a, 2b, ³ Mechlorethamine, Pentostatin ★★★ , Prednisone, Rituximab, ¹ Sodium Phosphate P 32, ¹ Uracil Mustard, Vincristine ¹	204.1_	Hemorrhagic Cystitis Mesna (Cyclophosphamide-induced, Ifosfamide-induced)	595.82, 995.2
Chronic Myelocytic Leukemia Aldesleukin, ¹ Arsenic Trioxide ★★★ , Busulfan, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, ³ Etoposide, ³ Hydroxyurea, Idarubicin ¹ ★★★ , Imatinib Mesylate, Interferon Alpha 2a, 2b, Mechlorethamine, Melphalan, Mercaptopurine, Mitomycin, ¹ Prednisone, ³ Sodium Phosphate P 32, ¹ Thioguanine, Topotecan, ¹ Uracil Mustard, Vincristine ¹	205.1_	Hodgkin's Lymphoma Amifostine, Bleomycin, Carboplatin, ¹ Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Cytarabine, ¹ Dacarbazine, Dexamethasone, Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, Gemcitabine Hydrochloride ¹ , Ifosfamide, ¹ Lomustine, Mechlorethamine, Melphalan, ¹ Mercaptopurine, ³ Methotrexate, ¹ Prednisone, Procarbazine, SGN-30 ★★★ , Thiotepa, ¹ Uracil Mustard, ³ Vinblastine, Vincristine	201._ _
Chronic Myelomonocytic Leukemia Daunorubicin, Mitomycin, Topotecan ¹	205.10	Hypercalcemia (associated with malignancy) Corticotropin, ¹ Dexamethasone, Etidronate, Gallium Nitrate, Hydrocortisone, ¹ Pamidronate, Plicamycin, Prednisone, Plicamycin, Zoledronic Acid ³	275.42
Colorectal ★Bevacizumab, [†] Capecitabine, Carmustine, ³ ★Cetuximab, [†] Floxuridine, Fluorouracil, Interferon Alpha 2a, 2b, ³ Irinotecan Hydrochloride, Leucovorin, Levamisole, Lomustine, Methotrexate, ¹ Mitomycin, Oxaliplatin, Raltitrexed (not available in US), ¹ Streptozocin, ¹ Trimetrexate, ¹ Vincristine ¹	153._, 154._	Kaposi's Sarcoma Alitretinoin ★★★ , BexaroteneHHH, Bleomycin, Cisplatin, ¹ Dactinomycin, Daunorubicin, ³ Daunorubicin Liposomal, Doxorubicin, Doxorubicin Liposomal, Etoposide, Interferon Alpha 2a, 2b, Paclitaxel, Thalidomide ³ ^{XX} , Vinblastine, Vincristine	176._
Cutaneous T-Cell Lymphoma Bexarotene ¹ ★★★ , Carmustine, ³ Chlorambucil, ¹ Denileukin, Diflutox ★★★ , Etoposide, ¹ Fludarabine Phosphate ³ , Interferon Alpha 2a, 2b, Mechlorethamine, ¹ Methotrexate, ³ Pentostatin ¹ ★★★ , Vinblastine, Vincristine ¹	202.1_, 202.2_, 202.8_	Kidney Aldesleukin, Amifostine, Cuplatin, ³ Cyclophosphamide, ¹ Fluorouracil, ³ ^{XX} Floxuridine, ¹ Interferon Alpha 2a, 2b, Medroxyprogesterone, Thalidomide, ³ Vinblastine, Vincristine	189.0, 189.1
Endometrial Cisplatin, Carboplatin, ¹ Cyclophosphamide, Dactinomycin, ¹ Doxorubicin, Etoposide, ¹ Fluorouracil, Goserelin, ¹ Hydroxyprogesterone, ³ Ifosfamide, ¹ Leuprolide, ¹ Medroxyprogesterone, Megestrol, Melphalan ¹ Methoxsalen, Paclitaxel, Tamoxifen ¹	182.0	Liver Arsenic Trioxide ★★★ , Cisplatin, Doxorubicin, ¹ Etoposide, Floxuridine, Fluorouracil, Mitoxantrone, ¹ Vincristine ¹	155.0, 155.2

Indication Index

INDICATION/Agent(s)	ICD-9 Code(s)
Lung (Small and/or Non-Small Cell)	162._
Altretamine, ¹ Amifostine, Carboplatin, Cisplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, Etoposide Phosphate, Fluorouracil, ★Gefitinib, ¹ Gemcitabine Hydrochloride, Irinotecan, ^{1,3} Ifosfamide, Lomustine, Mechlorethamine, Methotrexate, Mitomycin, Paclitaxel, Porfimer Sodium, ¹ Procarbazine, Topotecan, Trimetrexate ★★★, Uracil Mustard, ³ Vinblastine, Vincristine, Vinorelbine Tartrate	
Malignant Peritoneal Effusion	197.6
Bleomycin, ¹ Chromic Phosphate P32, ¹ Mechlorethamine, Thiotepa	
Malignant Pleural Effusion	197.2
Bleomycin, Chromic Phosphate P32, ¹ Mechlorethamine, Thiotepa	
Melanoma	172._
Aldesleukin, Amifostine, Asparaginase ¹ (melanosarcoma), Bleomycin, ¹ Carboplatin, ¹ Carmustine, Cisplatin, Dacarbazine, Hydroxyurea, Interferon Alpha 2a, 2b, Lomustine, ¹ Melphalan, Tamoxifen, ¹ Temozolomide, ¹ Thalidomide ³ ××, Vinblastine, Vincristine ¹	
Mesothelioma	163._
Cisplatin, ³ ★Pemetrexed [†]	
Multiple Myeloma	203.0_
Arsenic Trioxide ★★★, Bortezomib, ³ Carmustine, Cyclophosphamide, Dexamethasone, ¹ Doxorubicin, Epoetin Alfa ³ , Etoposide, ¹ Interferon Alpha 2a, 2b, Lomustine, ¹ Melphalan, Pamidronate Disodium, Prednisone, ¹ Procarbazine, ¹ Thalidomide, Vincristine, Zoledronic Acid ¹	
Myelodysplastic Syndromes	238.7
Amifostine, ¹ Arsenic Trioxide ★★★, Cytarabine, ¹ Epoetin Alfa, Filgrastim, Sargramostim, ★Thalidomide, ¹ Topotecan Hydrochloride ¹	
Neuroblastoma	160._ to 194._
Cisplatin, ¹ Carboplatin, ³ ×× Cyclophosphamide, Dacarbazine, ³ Daunorubicin, ¹ Doxorubicin, Etoposide, Ifosfamide, ¹ Teniposide, ¹ Vinblastine, ¹ Vincristine	
Neutropenia	288.0
Filgrastim (Chemotherapy-induced, assoc. with bone marrow transplant), Pegfilgrastim, Sargramostim (assoc. with bone marrow transplant, chemotherapy-induced, including chemotherapy assoc. with acute myelogenous leukemia)	
Non-Hodgkin's Lymphoma	200.__, 202.__
Aldesleukin ¹ ★★★, Amifostine, Asparaginase, Bleomycin, Carboplatin, ¹ Carmustine, Chlorambucil, Cisplatin, Cladribine, ¹ Cyclophosphamide, Cytarabine, Daunorubicin, ¹ Dexamethasone, ³ Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, Fludarabine Phosphate, Gemcitabine Hydrochloride ¹ , Ifosfamide, Interferon Alpha 2a, 2b, Leucovorin, ¹ Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, ¹ Prednisone, Procarbazine, Rituximab, Teniposide, ¹ Uracil Mustard, Vinblastine, Vincristine	
Osteosarcoma	170._, 198.5 (secondary code)
Bleomycin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, ¹ Ifosfamide, Interferon Alpha 2a, 2b, ³ Leucovorin, Melphalan, ³ Methotrexate, Vincristine, Zoledronic Acid ¹	

INDICATION/Agent(s)	ICD-9 Code(s)
Ovary	183.0
Altretamine, ¹ Amifostine, Carboplatin, Chlorambucil, Chromic Phosphate P 32, ¹ Cisplatin, Cyclophosphamide, Dactinomycin, ³ Docetaxel, ¹ Doxorubicin, Doxorubicin Liposomal, Epirubicin Hydrochloride, ¹ Etoposide, Floxuridine, Fluorouracil, Gemcitabine, Hydroxyurea, ¹ Ifosfamide, Interferon Alpha 2a, 2b, ³ Melphalan, Methotrexate, ¹ Paclitaxel, Thalidomide ³ ××, Thiotepa, Topotecan Hydrochloride, Treosulfan, ¹ Uracil Mustard, ³ Vinorelbine ¹	
Ovary (Germ Cell)	183.9
Bleomycin, Chlorambucil, Cisplatin, Cyclophosphamide, Dactinomycin, ¹ Doxorubicin, Doxorubicin Liposomal, ¹ Etoposide, ¹ Ifosfamide ¹ Vinblastine, ¹ Vincristine ¹	
Pancreas	157._
Bleomycin ★★★, Dacarbazine, Doxorubicin, ¹ Fluorouracil, Gemcitabine Hydrochloride, Ifosfamide, ¹ Interferon Alpha 2a, 2b, ³ Methotrexate, ¹ Mitomycin, Octreotide, Trimetrexate ¹ ★★★	
Paget's Disease of Bone	731.0
Etidronate, Pamidronate, Plicamycin	
Penis	187.1 to 187.4
Bleomycin, Cisplatin ³ ××, Fluorouracil, ¹ Methotrexate ¹	
Peritoneal	158.8, 158.9, 197.6
Carboplatin, ¹ Cisplatin, ¹ Paclitaxel ¹	
Prostate	185
Aminoglutethimide, ¹ Bicalutamide, ¹ Buserelin, ¹ Chlorotrianisene Chromic Phosphate P 32, ¹ Cisplatin, Cyclophosphamide, Dexamethasone, ¹ Diethylstilbestrol, Docetaxel, ¹ Doxorubicin, Estradiol, Estradiol Valerate, Estramustine, Estrogens (Conjugated & Esterified), Estrone, Ethinyl Estradiol, Fluorouracil, ¹ Flutamide, Goserelin, ¹ Ketoconazole, Leuprolide, Melphalan, ³ Mitoxantrone, Nilutamide, Paclitaxel, ¹ Prednisone, ¹ Thalidomide ³ ××, Triptorelin Pamoate, ³ Vinblastine ¹	
Retinoblastoma	190.5
Carboplatin, Cisplatin, ¹ Cyclophosphamide, Doxorubicin, ¹ Etoposide, ¹ Vincristine ¹	
Skin	173._
Bleomycin, Cisplatin, ¹ Fluorouracil, Interferon Alpha 2a, 2b, Masoprocol, Methoxsalen ¹	
Soft-Tissue Sarcomas	171._
Bleomycin, ¹ Cisplatin, Cyclophosphamide, Dacarbazine, Dactinomycin, Daunorubicin, ¹ Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, Ifosfamide, Melphalan, ³ Methotrexate, ¹ Vinblastine, ¹ Vincristine	
Squamous Cell Carcinomas of Skin	173._
Bleomycin	
Stomach	151._
Carmustine, Cisplatin, Docetaxel, ¹ Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, ¹ Fluorouracil, Imatinib Mesylate ¹ (GIST), Methotrexate, ¹ Mitomycin, Paclitaxel ¹	

Indication Index

AGENT/Indication(s)	ICD-9 Code(s)
Testes	186._
Bleomycin, Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Etoposide Phosphate, Ifosfamide, Melphalan, ³ Paclitaxel, ¹ Plicamycin, Vinblastine	
Thymoma	164.0, 164.8
Cisplatin, Cyclophosphamide, ¹ Doxorubicin, ¹ Etoposide, ¹ Ifosfamide ¹	
Thyroid	193
Bleomycin, ¹ Cisplatin, Doxorubicin, Levothyroxine, Liothyronine, Liotrix, Sodium Iodide I 131, ¹ Thyroglobulin, Thyroid, Thyrotropin	
Trophoblastic Neoplasms	181, 236.1, 186.9
Bleomycin, Cisplatin, Cyclophosphamide, ¹ Dactinomycin, Doxorubicin, ¹ Etoposide, Leucovorin, ¹ Methotrexate, Vinblastine, Vincristine ¹	
Uterus	182._
Amifostine, Hydroxyprogesterone, Ifosfamide ³ ^{XX}	
Vulva	184.1, 184.2, 184.3, 184.4
Bleomycin	
Wilms' Tumor	189.0
Carboplatin ³ ^{XX} , Cisplatin, ¹ Cyclophosphamide Dactinomycin, Daunorubicin, ¹ Doxorubicin, Etoposide, Ifosfamide, Vincristine	

MOVING? DON'T MISS A SINGLE ISSUE!

Remember to let us know. Just fill out the form below and mail or fax it with your old mailing label to the Association of Community Cancer Centers, 11600 Nebel St., Suite 201, Rockville, MD 20852. Fax: 301-770-1949

First	M.I.	Last	Degree(s)
Title			
Affiliation			
Address			
State	State	Zip Code	
Phone	Fax		
E-mail			

www.accc-cancer.org

The Association of Community Cancer Centers' Web Site—
Visited by more than 50,000 individuals each month!

Here are just some of the unique features online.

Daily News

Check out the news and information that is timely and relevant to oncology. You'll find the latest updates about legislative and regulatory issues that affect your program's or practice's bottom line. And you'll find analysis to explain what it all means.

Featured Articles

Model programs, new strategies, reimbursement tips—from joint ventures and telemedicine to billing and coding. You'll find articles to satisfy the information needs of the entire cancer team.

Drug Information

Receive the latest approval information on off-label indications and new drug approvals.

Find a Cancer Center

Locate an ACCC-member institution or cancer center in your state.

State Oncology Societies

Find the latest news and information for your state oncology society.

Public Policy Center

Find the latest on legislative and regulatory news that will affect your cancer program and practice.

Career Resource Center

Advance your career with a wealth of information, including employment opportunities and career resources.

And more!



Your Online Source for Timely News and Information in the Field of Oncology.

Median Figures for Selected Cancer Agents ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT	Dosage	Quantity	Range of AWP*	Median AWP**
Alemtuzumab	30 mg (J9010 per 10 mg)	1	\$1,845.90	\$1,845.90
Asparaginase	10,000 units (J9020)	1	\$65.91	\$65.91
Bleomycin Sulfate	15 units (J9040)	1	\$177.19-309	★306.80
Carboplatin	50 mg (J9045) 150 mg 450 mg	1 1 1	\$163.84 491.48 1,474.46	\$163.84 491.48 1,474.46
Carmustine	100 mg (J9050)	1	\$149.99	\$149.99
★Cetuximab[†]	100 mg	1	\$576.00	\$576.00
Cisplatin	50 mg (J9062)	1	\$84-249.98	\$222.00
Cladribine	(J9065 per 1 mg) 10 mg	1	\$540-681.49	\$540
Cyclophosphamide (lyophilized)	100 mg (J9093) 200 mg (J9094) 500 mg (J9095) 1 gm (J9096) 2 gm (J9097)	1 1 1 1 1	\$6.45 11.76 25.71 51.43 102.89	\$6.45 11.76 25.71 51.43 102.89
Cyclophosphamide (non-lyophilized)	100 mg (J9070) 200 mg (J9080) 500 mg (J9090) 1 gm (J9091) 2 gm (J9092)	1 1 1 1 1	\$6.03 11.46 24.06 48.14 96.26	\$6.03 11.46 24.06 48.14 96.26
Dacarbazine	200 mg (J9140)	1	\$22.68-27.73	\$25.20
Dactinomycin	0.5 mg (J9120)	1	\$14.60	\$14.60
Daunorubicin	20 mg (J9150)	1	\$161.31-169.80	\$169.75
Diethylstilbestrol	250 mg (J9165)	1	\$15.17	\$15.17
Docetaxel	20 mg (J9170)	1	\$376.75	\$376.75
Dolasetron Mesylate	100mg 10mg (J1260)		\$173.16	\$173.16

AGENT	Dosage	Quantity	Range of AWP*	Median AWP**
Doxorubicin	10 mg (J9000) 20 mg 50 mg	1 1 1	\$10.20-44.40 19.92-26.40 50.40-132.00	\$13.20 23.16 64.80
Doxorubicin, Liposomal	20 mg 50 mg (J9001 per 10 mg)	1 1	\$877.25 2,193.13	877.25 2,193.13
Etidronate	300 mg (J1436)	1	\$63.60	\$63.60
Etoposide	100 mg (J9182)	1	\$18.00-157.60	\$105.75
Etoposide Phosphate	100 mg (J9999)	1	\$132.83	\$132.83
Floxuridine	500 mg (J9200)	1	★\$144.00-155.00	\$150.00
Fludarabine Phosphate	50 mg (J9185)	1	\$374.81	\$374.81
Fluorouracil	500 mg (J9190)	1	\$2.18-3.75	\$2.84
Gemcitabine Hydrochloride	200 mg (J9201) 1 gm	1 1	★\$127.38 ★636.88	\$127.38 636.88

KEY

*Ranges of average wholesale prices (AWPs) are from the February 2004 *Redbook Update*. The information contained in this list is derived from sources that ACCC believes to be accurate and reliable. Because error, whether human or mechanical, is possible, ACCC makes no representation or warranty, expressed or implied, as to the accuracy, timeliness, or completeness of any information contained herein. Some dosages may not be available. Not all dosages are listed. Agents selected are commonly used injectables. ACCC shall have no liability to any person for any loss or damage resulting from any error herein.

**The median is the point on the scale above which—and correspondingly below which—50 percent of the cases lie. With an even number of items, the mean, or average, is taken of the value of the two middle items.

★ = Item has been added or changed since last issue.

Median Figures for Selected Cancer Agents ■ ANTINEOPLASTICS AND THEIR ADJUNCTS

AGENT	Dosage	Quantity	Range of AWP*s*	Median AWP**	AGENT	Dosage	Quantity	Range of AWP*s*	Median AWP**
Goserelin	3.6 mg (J9202)		\$469.99	469.99	Paclitaxel	30 mg (J9265)	1	\$170.70-182.63	\$174.03
Granisetron Hydrochloride	100 mcg (J1626)	1	19.52	19.52	Pamidronate Disodium	30 mg (J2430)	1	\$279.86-290	\$284.93
	1 mg	1	\$195.20	\$195.20		60 mg	1	428.97	428.97
	4 mg	1	780.80	780.80		90 mg	1	839.60-872	855.80
Idarubicin	5 mg (J9211)	1	\$442.04-471.50	\$456.77	Pegaspargase	(J9266 per single dose vial)			
	10 mg	1	884.06-943.00	913.53		3,750 units		\$1,391.21-1,625.00	\$1,508.11
Ifosfamide	1 gm (J9208)		\$158.29-169.84	\$164.07	★Pemetrexed	500 mg	1	\$2,437.50	\$2,437.50
	3 gm	1	509.51	509.51	Plicamycin	2.5 mg (J9270)	1	\$98.74	\$98.74
Irinotecan Hydrochloride	(J9206 for 20 mg.)				Rituximab	100 mg (J9310)	1	\$527.50	\$527.50
	40 mg	1	\$321.85	\$321.85	Streptozocin	1 gm (J9320)	1	\$148.92	\$148.92
	100 mg	1	804.65	804.65	Teniposide	50 mg	1	\$283.58	\$283.58
Leucovorin Calcium	50 mg (J0640)	1	\$18.40	\$18.40	Thiotepa	15 mg (J9340)	1	\$98.50-148.44	\$118.20
	100 mg	1	35.00	35.00	Topotecan Hydrochloride	4 mg (J9350)	1	★\$882.72	\$882.72
	200 mg	1	78.00	78.00	Trastuzumab (Herceptin)	440 mg	1	\$2,692.38	\$2,692.38
	350 mg	1	137.94-137.95	137.95	Vinblastine	(J9360 for 1 mg)			
Leuprolide	3.75 mg (J1950)	1	★\$569.59	\$569.59		10 mg	1	\$11.52-40.54	\$39.01
	7.5 mg (J9217)	1	★685.21	685.21	Vincristine	1 mg (J9370)	1	\$31.75-41.50	\$35.92
Mechlorethamine	10 mg (J9230)	1	\$12.64	\$12.64		2 mg (J9375)	1	38.25-83.00	71.82
Melphalan	50 mg (J9245)	1	\$442.21	\$442.21		5 mg (J9380)	1	162.71	162.71
Methotrexate	20 mg	1	\$5.03	\$5.03	Vinorelbine Tartrate	10 mg (J9390)	1	★\$90.24-114.74	\$94.06
	50 mg (J9260)	1	4.75-6.88	5.82	Zoledronic Acid	4 mg	1	\$959.41	\$959.41
	100 mg	1	8.50-8.75	8.63					
	200 mg	1	16.73-17.50	17.12					
	250 mg	1	20.48-26.88	23.68					
	1 gm	1	61.44	61.44					
Mitomycin	5 mg (J9280)	1	\$67.20-134.11	\$134.11					
	20 mg (J9290)	1	218.40-452.91	340.21					
	40 mg (J9291)	1	300.00-915.09	607.55					
Mitoxantrone	(J9293 per 5 mg)								
	20 mg	1	\$1,513.06	\$1,513.06					
	25 mg	1	1,891.29	1,891.29					
	30 mg	1	2,269.59	2,269.59					
Ondansetron Hydrochloride	(J2405 per 1 mg)								
	40 mg	1	\$256.40	\$256.40					

Median Figures for Selected Cancer Agents

■ BIOLOGICAL RESPONSE MODIFIERS

AGENT	Dosage	Quantity	Range of AWP*s	Median AWP**
Aldesleukin	(J9015 per single dose vial)			
	22 million units	1	★\$811.50	811.50
Darbepoetin Alfa	5 mcgm	1	\$24.95	\$24.95
	(J0880)★, (Q0137 per 1 mcgm)			
	100 mcgm	1	\$498.75	\$498.75
	150 mcgm	1	\$748.13	\$748.13
	200 mcgm	1	\$997.50	\$997.50
	300 mcgm	1	\$1,496.25	\$1,496.25
	★for use in physician office setting only			
Epoetin Alfa	(Q0136 per 1,000 units)			
	2,000 units	1	\$26.71-26.92	\$26.82
	3,000 units	1	40.07-40.38	40.23
	4,000 units	1	53.42-53.83	53.63
	10,000 units	1	133.56-134.59	134.08
	20,000 units	1	267.12-289.46	278.29
40,000 units	1	534.24-568	551.12	
Filgrastim	300 mcgm (J1440)	1	\$227.60	\$227.60
	480 mcgm (J1441)	1	362.60	362.60
Immune Globulin	500 mg (J1561)	1	\$64.80	\$64.80
	5 gm (J1562)	1	412.80-504.65	500.00
Interferon Alpha-2a	3 million units	1	\$34.97	\$34.97
	(J9213)			
Interferon Alpha-2b	3 million units	1	\$42.63	42.63
	5 million units	1	71.04	71.04
	10 million units	1	156.58	156.58
	18 million units	1	281.87	281.87
	25 million units	1	391.51	391.51
	50 million units	1	783.01	783.01
Levamisole	50 mg.	1	\$5.61	\$5.61
Octreotide	1,000 mcgm	1	\$110.48	\$110.48
	5,000 mcgm	1	543.61	543.61
Oprelvekin	5 mg (J2355)	1	\$270.14	\$270.14
Sargramostim	50 mcgm (J2820)•	-	-	-
	250 mcgm (J2820)	1	\$152.95	152.95
	500 mcgm (J2820)	1	305.90	305.90
	•use this billing unit with both vial sizes			